immune-mediated adverse events – Talk Bio

Actionable Insights Powered by AI

Merck Pauses Phase 3 TIGIT Trial Due to Immune-Mediated Adverse Events

12 months ago talkbio0Tagged Discontinuation (procedure), immune-mediated adverse events, Merck, Phase 3 trial, TIGIT gene

Merck, Phase 3 Trial, TIGIT, Immune-mediated Adverse Events, Discontinuations